IPM Take
The success of immunotherapy in earlier endometrial cancer has created a new post-immunotherapy treatment problem. TroFuse-005 provides the strongest answer yet in that setting, but the survival gain comes with meaningful haematological and mucosal toxicity that belongs in the access and value discussion.
Executive Summary
The Phase III TroFuse-005/ENGOT-en23/GOG-3095 trial randomised 776 patients across 242 centres in 31 countries and regions after previous platinum chemotherapy and PD-1/PD-L1 therapy. Sacituzumab tirumotecan improved median progression-free survival to 7.2 months versus 3.9 months with physician-choice chemotherapy and median overall survival to 19.0 versus 12.1 months. The hazard ratios were 0.59 for progression or death and 0.68 for death. Grade 3 or higher adverse events occurred in 69% of patients receiving sac-TMT and 57% receiving chemotherapy.
Why it matters
- Patients / advocates: A meaningful survival gain emerges in a setting with few strong options.
- Clinicians: The post-platinum, post-immunotherapy sequence becomes more defined.
- Payers: ADC acquisition and toxicity management will become part of a growing gynaecological oncology budget question.
- Regulators: The U.S. application has already entered priority review.
The Phase III TroFuse-005 results published in The Lancet address a problem created partly by progress itself. Checkpoint inhibitors have moved earlier in endometrial cancer and improved outcomes for many patients, but when disease progresses after both platinum chemotherapy and immunotherapy, the evidence base becomes much thinner. Sacituzumab tirumotecan now offers a randomised survival signal in exactly that setting, extending median overall survival by almost seven months and nearly doubling objective response compared with doxorubicin or paclitaxel.
The result also strengthens the broader case for TROP2-directed ADCs, but it should not be reduced to a platform victory. Endometrial cancer incidence and mortality are increasing in many countries, and the patients entering TroFuse-005 had already received the major systemic treatments that increasingly define contemporary care. A therapy that delays progression and improves overall survival after those options have failed fills a clinically meaningful gap rather than simply adding another drug to an already crowded sequence.
The toxicity profile, however, makes implementation more demanding than the efficacy headline suggests. Severe adverse events were more frequent with sac-TMT, including clinically relevant anaemia, neutropenia and mucosal toxicity. That means the value proposition will depend not only on drug acquisition but on supportive care, monitoring and the ability of gynaecological oncology services to manage repeated ADC treatment. The survival gain is substantial enough to justify serious attention; the treatment burden is substantial enough to belong in the same conversation.

